This trial is evaluating whether Descartes 08 will improve 1 primary outcome in patients with Multiple Myeloma. Measurement will happen over the course of 2 years.
This trial requires 30 total participants across 2 different treatment groups
This trial involves 2 different treatments. Descartes 08 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
Findings from a recent study highlights a number of risk factors which may have a role in the development of multiple myeloma. Smoking is a significant environmental risk factor for the development of multiple myeloma.
The [S]cenario described represents a plausible case of cure. This scenario is not necessarily possible, and this scenario should be considered separately from the general scenario. In particular, the [S]cenario is possible when all clinical and biopsy elements agree and there is no evidence for disease progression for at least 4 months. This scenario has been tested in several patients and has been found to have a high incidence of cure (60% to 96% of patients.) This cure could have important implications for patient management and treatment.
Mucositis and weight loss are the earliest clinical signs or symptoms of myeloma. Pain and night sweats are the main clinical signs when myeloma is present. Lhermitte's sign is another clinical symptom of myeloma. Symptoms such as lethargy, and neurological deficits occur when myeloma progresses to anaemia and/or myeloma bone disease. Osmotic fragility is indicative of myeloma.
The incidence of MM has risen in recent years and the most common sites for MM are the spine and bone. The most common age at diagnosis for patients with MM is 66. The number of patients with MM in the US is estimated to be around 20,000 patients per year.\n
Multiple myeloma treatment is commonly used, either alone or as complement in other standard treatments. Monoclonal gammopathy of undetermined significance is commonly treated with alkylating agents. Patients with smoldering multiple myeloma are frequently treated with statins to reduce high lipid levels associated with this condition.
For those who wish to keep using medication, this information will help them know how they might be affected by the medications they have or have changed in recent years. If they have noticed side effects, they can take them directly to their physician and have them checked out. Some common, but mild, side effects of descartes 08 include: numbness, swelling, burning, and other types of pain. If they are taking drugs that have not been prescribed to them, their physician should also be notified. They should tell their physician all of their prescription drug usage and the amount and frequency of use.
The nromality of a group of people who were diagnosed with MM was about one third lower than that of the general population. To increase the detection rate of MM, screening programmes should start before the ndiscretionary age; the age range 45-64 years should be screened for MM. The ndiscretionary age of 65 years should receive screening for MM.
Data from a recent study suggest that the occurrence of multiple myeloma is significantly increased in families when at least one member has one to two risk alleles. This finding underscores the importance of genetic counseling, particularly in families with multiple first-degree relatives affected early in life.
The risk of developing multiple myeloma increases as the number of risk factors increases. Multiple factors are associated with an increased risk of multiple myeloma, particularly cigarette smoking and viral infection but not sun exposure.
Findings from a recent study showed that, in vitro and in vivo studies have suggested that D8 could effectively inhibit multiple myeloma, although a larger number of patients are necessary to validate this hypothesis.